Jeffrey S. Heier
Ophthalmic Consultants of Boston
Boston
Massachusetts
USA
Name/email consistency: high
- Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. Heier, J.S., Brown, D., Ciulla, T., Abraham, P., Bankert, J.M., Chong, S., Daniel, P.E., Kim, I.K. Ophthalmology (2011)
- Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. Heier, J.S., Awh, C.C., Busbee, B.G., Waterbury, L.D., Daniel, P., Stoller, G.L., Cleary, T.S. Retina (Philadelphia, Pa.) (2009)
- Pathology beyond neovascularization: new targets in age-related macular degeneration. Heier, J.S. Retina (Philadelphia, Pa.) (2009)
- Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Heier, J.S., Boyer, D.S., Ciulla, T.A., Ferrone, P.J., Jumper, J.M., Gentile, R.C., Kotlovker, D., Chung, C.Y., Kim, R.Y. Arch. Ophthalmol. (2006)
- Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Heier, J.S., Topping, T.M., Baumann, W., Dirks, M.S., Chern, S. Ophthalmology (2000)
